Finally, there is a need to leverage multimodal clinical data beyond structured EHR findings to truly understand the holistic impact of GLP-1s with outcomes captured from different types of structured and unstructured data
Ann Internal Med
Oral semaglutide 50 mg resulted in 17.4% WL compared to 1.8% with placebo (Fig
Ziwuliuzhu acupuncture modulates clock mRNA, Bmal1 mRNA and melatonin in insomnia rats
Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists, GLP-IRAs, GLP-1 analogs, or incretin mimetics, are a class of medications that activate the GLP-1 receptor, leading to reduced blood sugar levels and decreased appetite, which in turn results in lower energy intake
The severity ranged from mild, occasional episodes to more persistent daily symptoms that required lifestyle or dietary adjustments